Anirban Maitra: Therapeutic targeting of Syndecan-1 axis in gastrointestinal cancers
Anirban Maitra shared on X:
“New preprint by Wantong Yao, Haoqiang Ying, Scott Kopetz.
Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. In preclinical models of Pancreatic Cancer and Colorectal Cancer, bypass of KRAS inhibition is accompanied by re-expression of cell surface SDC1 via a YAP-SDC1 axis, which restores macropinocytosis, and RTK-dependent growth.
You can hear Wantong Yao speak at the AACR Special Conference on Pancreatic Cancer next month in Boston, in the Tumor Cell Biology Session.”
Source: Anirban Maitra/X
Authors: Mitsunobu Takeda, Madelaine S. Theardy, Alexey Sorokin, Oluwadara Coker, Preeti Kanikarla, Shuaitong Chen, Zecheng Yang, Phuoc Nguyen, Yongkun Wei, Jun Yao, Xiaofei Wang, Liang Yan, Yanqing Jin, Yiming Cai, Masakatsu Paku, Ziheng Chen, Kara Z. Li, Francesca Citron, Hideo Tomihara, Sisi Gao, Angela K. Deem, Jun Zhao, Huamin Wang, Samir Hanash, Ronald A. DePinho, Anirban Maitra, Giulio F. Draetta, Haoqiang Ying, Scott Kopetz, Wantong Yao
Dr. Anirban Maitra serves as Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center. He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.